retatrutide clinical trials latest Retatrutide: A Promising Option for Non-Diabetic Weight Loss in Retatrutide for weight loss: Study

Mean HbA1c was 8.3% and mean BMI was 32.1 kg/m2

The emphasis is always on patient safety, realistic goals, and long term success

Saxenda, the second to be approved, only achieved middling weight-management results for a large share of those who took it, and physicians were reticent to prescribe weight-loss medications after the disastrous effects of drugs such as fen-phen were revealed in the late 90s

Furthermore, GLP-1 signaling score was closely associated with TME-related pathways, including EMT, antigen processing machinery, CD8 T effector, immune checkpoint, DNA damage and mismatch repair in pan-cancer (Figure 8A)

What is happening in my gut

The Bottom Line The excitement around GLP-1 weight loss therapies has highlighted just how powerful this hormone is in regulating appetite, blood sugar, and metabolic health